Fortress Biotech Files 8-K

Ticker: FBIOP · Form: 8-K · Filed: Dec 15, 2025 · CIK: 1429260

Sentiment: neutral

Topics: corporate-filing, 8-K, financial-reporting

Related Tickers: FBIO

TL;DR

FBIO filed an 8-K on 12/15/25, standard corporate update.

AI Summary

Fortress Biotech, Inc. filed an 8-K on December 15, 2025, reporting on other events and financial statements. The filing details the company's incorporation in Delaware and its fiscal year end of December 31. It also lists its SEC file number as 001-35366 and its IRS Employer Identification Number as 20-5157386.

Why It Matters

This 8-K filing provides essential corporate information and updates for Fortress Biotech, Inc., which is crucial for investors and stakeholders to stay informed about the company's regulatory compliance and financial reporting status.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting corporate information and financial statements, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Fortress Biotech, Inc.?

The primary purpose of this 8-K filing is to report on 'Other Events' and 'Financial Statements and Exhibits' as of December 15, 2025.

When was Fortress Biotech, Inc. incorporated and what is its fiscal year end?

Fortress Biotech, Inc. was incorporated in Delaware and its fiscal year ends on December 31.

What are the key identification numbers associated with Fortress Biotech, Inc. in this filing?

The filing lists the Commission File Number as 001-35366 and the IRS Employer Identification No. as 20-5157386.

What is the business and mailing address for Fortress Biotech, Inc. as provided in the filing?

The business and mailing address for Fortress Biotech, Inc. is 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154.

What is the SIC code for Fortress Biotech, Inc.?

The Standard Industrial Classification (SIC) code for Fortress Biotech, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-12-15 08:30:27

Filing Documents

01 Other Events

Item 8.01 Other Events. On December 15, 2025, Fortress Biotech, Inc. (the " Company ") issued a press release announcing that the U.S. Food and Drug Administration accepted the resubmission of the New Drug Application (" NDA ") for CUTX-101 as a Class 1 resubmission and provided a Prescription Drug User Fee Act (PDUFA) target action date of January 14, 2026 for the NDA. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits . (d) Exhibits. The following exhibit is furnished herewith: 99 Exhibit Number Description 99.1 Press release of Fortress Biotech, Inc. dated December 15, 2025. 104 Cover Page Interactive Data File (the cover page XBRL tags are imbedded in the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Fortress Biotech, Inc. (Registrant) Date: December 15, 2025 By: /s/ David Jin David Jin Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing